L. Fonctions, LncARN et régulation de l'expression génétique, p.121

G. Gatta, J. Van-der-zwan, P. Casali, S. Siesling, D. Tos et al., Rare cancers are not so rare: The rare cancer burden in Europe, European Journal of Cancer, vol.47, issue.17, 2011.
DOI : 10.1016/j.ejca.2011.08.008

URL : https://hal.archives-ouvertes.fr/hal-00719112

A. Belot, P. Grosclaude, N. Bossard, E. Jougla, E. Benhamou et al., Cancer incidence and mortality in France over the period 1980-­?2005. Rev Epidemiol Sante Publique, pp.159-75, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00338335

C. Pui, Childhood Leukemias, New England Journal of Medicine, vol.332, issue.24, pp.1618-1648, 1995.
DOI : 10.1056/NEJM199506153322407

V. Aquino, Acute myelogenous leukemia, Current Problems in Pediatric and Adolescent Health Care, vol.32, issue.2, pp.50-58, 2002.
DOI : 10.1067/mps.2002.121791

F. Chin-­?to and G. Brodeur, Down's syndrome and leukemia: Epidemiology, Genetics, Cytogenetics and Mechanisms of leukomogenesis, Cancer Genetics and Cytogenetics, pp.55-76, 1987.

A. Bruwier and C. Chantrain, Hematological disorders and leukemia in children with Down syndrome, European Journal of Pediatrics, vol.55, issue.9, pp.1301-1308, 2012.
DOI : 10.1016/j.pcl.2007.11.001

S. Swerdlow, E. Campo, N. Harris, E. Jaffe, S. Pileri et al., WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 2008.

W. Song, M. Sullivan, R. Legare, S. Hutchings, X. Tan et al., Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia, Nat Genet, vol.23, issue.2, pp.166-75, 1999.

S. Dowton, D. Beardsley, D. Jamison, S. Blattner, and F. Li, Studies of a familial platelet disorder, Blood, vol.65, issue.3, pp.557-63, 1985.

C. Fonatsch, The role of chromosome 21 in hematology and oncology, Genes, Chromosomes and Cancer, vol.55, 2010.
DOI : 10.1001/jama.1954.73690210004006b

M. Ichikawa, A. Yoshimi, M. Nakagawa, N. Nishimoto, N. Watanabe-­?okochi et al., A role for RUNX1 in hematopoiesis and myeloid leukemia, International Journal of Hematology, vol.3, issue.6, pp.726-760
DOI : 10.4161/cc.3.6.951

M. Hauptmann, P. Stewart, J. Lubin, B. Freeman, L. Hornung et al., Mortality From Lymphohematopoietic Malignancies and Brain Cancer Among Embalmers Exposed to Formaldehyde, JNCI Journal of the National Cancer Institute, vol.1, issue.7, pp.1696-708, 2009.
DOI : 10.13031/2013.19461

L. Zhang, X. Tang, N. Rothman, R. Vermeulen, J. Z. Shen et al., Occupational Exposure to Formaldehyde, Hematotoxicity, and Leukemia-Specific Chromosome Changes in Cultured Myeloid Progenitor Cells, Cancer Epidemiology Biomarkers & Prevention, vol.19, issue.1, pp.80-88, 2010.
DOI : 10.1158/1055-9965.EPI-09-0762

S. Larsson and A. Wolk, Overweight and obesity and incidence of leukemia: A meta-analysis of cohort studies, International Journal of Cancer, vol.6, issue.6, pp.1418-1439, 2007.
DOI : 10.1038/nri1937

S. Puumala, J. Ross, R. Aplenc, and L. Spector, Epidemiology of childhood acute myeloid leukemia. Pediatric Blood & Cancer, pp.728-761, 2013.

J. Goldman and J. Melo, Chronic Myeloid Leukemia ??? Advances in Biology and New Approaches to Treatment, New England Journal of Medicine, vol.349, issue.15, pp.1451-64, 2003.
DOI : 10.1056/NEJMra020777

R. Silver, The blast phase of chronic myeloid leukaemia. Best Practice & Research Clinical Haematology, pp.387-94, 2009.

A. Quintás-­?cardama and J. Cortes, Molecular biology of bcr-abl1-positive chronic myeloid leukemia, Blood, vol.113, issue.8, pp.1619-1649, 2009.
DOI : 10.1182/blood-2008-03-144790

F. Van-leeuwen, 4 Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment, Bailli??re's Clinical Haematology, vol.9, issue.1, pp.57-85, 1996.
DOI : 10.1016/S0950-3536(96)80037-0

S. Frohling, Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications, Journal of Clinical Oncology, vol.23, issue.26, pp.6285-95, 2005.
DOI : 10.1200/JCO.2005.05.010

Y. Chalandon and J. Schwaller, Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies, haematologica, vol.90, issue.7, pp.949-68, 2005.

H. Ahuja, L. Popplewell, L. Tcheurekdjian, and M. Slovak, NUP98 gene rearrangements and the clonal evolution of chronic myelogenous leukemia, Genes, Chromosomes and Cancer, vol.91, issue.4, pp.410-415, 2001.
DOI : 10.1073/pnas.91.22.10722

F. Ferrara and C. Schiffer, Acute myeloid leukaemia in adults. The Lancet, pp.484-95, 2013.

F. Huguet and C. Récher, Leucémies aigues de l'adulte. Hematologie

L. Godley and R. Larson, Therapy-Related Myeloid Leukemia, Seminars in Oncology, vol.35, issue.4, 2008.
DOI : 10.1053/j.seminoncol.2008.04.012

R. Larson, L. Beau, and M. , Therapy-­?related myeloid leukaemia: A model for leukemogenesis in humans. Chemico-­?Biological Interactions, pp.153-154187, 2005.

T. Haferlach, Morphologic Dysplasia in De Novo Acute Myeloid Leukemia (AML) Is Related to Unfavorable Cytogenetics but Has No Independent Prognostic Relevance Under the Conditions of Intensive Induction Therapy: Results of a Multiparameter Analysis From the German AML Cooperative Group Studies, Journal of Clinical Oncology, vol.21, issue.2, pp.256-65, 2003.
DOI : 10.1200/JCO.2003.08.005

C. Preudhomme, H. Leroy, and S. Botton, Facteurs biologiques du pronostic des leucémies aiguës myéloïdes. Hématologie, pp.59-67, 2004.

M. Sanz and A. Sempere, 3 Immunophenotyping of AML and MDS and detection of residual disease, Bailli??re's Clinical Haematology, vol.9, issue.1, pp.35-55, 1996.
DOI : 10.1016/S0950-3536(96)80036-9

R. Casasnovas, F. Slimane, R. Garand, G. Faure, L. Campos et al., Immunological classification of acute myeloblastic leukemias: relevance to patient outcome, Leukemia, vol.78, issue.Suppl 1, pp.515-542, 2003.
DOI : 10.3109/10428199409052681

A. Cuneo, A. Ferrant, J. Michaux, M. Boogaerts, H. Demuynck et al., Cytogenetic profile of minimally differentiated (FAB M0) acute myeloid leukemia: correlation with clinicobiologic findings. Blood, pp.3688-94, 1995.

H. Kao, D. Liang, J. Wu, M. Kuo, P. Wang et al., Gene Mutation Patterns in Patients with Minimally Differentiated Acute Myeloid Leukemia, Neoplasia, vol.16, issue.6, 2014.
DOI : 10.1016/j.neo.2014.06.002

C. Bloomfield, A. Goldman, D. Hassfeld, and A. De-la-chapelle, Fourth International Workshop on Chromosomes in Leukemia 1982: Clinical significance of chromosomal abnormalities in acute nonlymphoblastic leukemia, Cancer Genet Cytogenet, 1984.

G. Perea, A. Lasa, A. Aventín, A. Domingo, N. Villamor et al., Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)], Leukemia, vol.18, issue.1, pp.87-94, 2006.
DOI : 10.1038/sj.leu.2403444

W. Kern, C. Haferlach, T. Haferlach, and S. Schnittger, Monitoring of minimal residual disease in acute myeloid leukemia. Cancer, pp.4-16, 2008.

A. Kohlmann, N. Nadarajah, T. Alpermann, V. Grossmann, S. Schindela et al., Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease, Leukemia, vol.21, issue.1, 2014.
DOI : 10.1016/j.beha.2007.11.013

S. Smith, Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series, Blood, vol.102, issue.1, pp.43-52, 2003.
DOI : 10.1182/blood-2002-11-3343

M. Slovak, V. Bedell, L. Popplewell, D. Arber, C. Schoch et al., 21q22 balanced chromosome aberrations in therapy-related hematopoietic disorders: Report from an International Workshop, Genes, Chromosomes and Cancer, vol.98, issue.4, pp.379-94, 2002.
DOI : 10.1073/pnas.171321298

I. Cowell and C. Austin, Mechanism of Generation of Therapy Related Leukemia in Response to Anti-Topoisomerase II Agents, International Journal of Environmental Research and Public Health, vol.56, issue.12, pp.2075-91, 2012.
DOI : 10.3390/cancers3044170

C. Seedhouse and N. Russell, Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemia, British Journal of Haematology, vol.94, issue.1, pp.513-542, 2007.
DOI : 10.1111/j.1432-1033.1994.00893.x

A. Giguère and J. Hébert, -positive acute leukemia, Genes, Chromosomes and Cancer, vol.93, issue.12, pp.1114-1136, 2013.
DOI : 10.1073/pnas.93.8.3444

K. Paulsson, A. Békássy, T. Olofsson, F. Mitelman, B. Johansson et al., A novel and cytogenetically cryptic t(7;21)(p22;q22) in acute myeloid leukemia results in fusion of RUNX1 with the ubiquitin-specific protease gene USP42, Leukemia, vol.350, issue.2, pp.224-233, 2006.
DOI : 10.1056/NEJMoa031046

Y. Zhang, N. Emmanuel, G. Kamboj, J. Chen, M. Shurafa et al., PRDX4, a member of the peroxiredoxin family, is fused toAML1 (RUNX1) in an acute myeloid leukemia patient with a t(X;21)(p22;q22). Genes, Chromosomes and Cancer, pp.365-70, 2004.

F. Mikhail, L. Coignet, N. Hatem, Z. Mourad, H. Farawela et al., A novel gene,FGA7, is fused toRUNX1/AML1 in a t(4;21)(q28;q22) in a patient with T-cell acute lymphoblastic leukemia, Genes, Chromosomes and Cancer, vol.88, issue.2, pp.110-118, 2004.
DOI : 10.1128/MCB.14.4.2404

T. Nguyen, L. Ma, M. Slovak, C. Bangs, A. Cherry et al., Identification of novelRunx1 (AML1) translocation partner genesSH3D19,YTHDf2, andZNF687 in acute myeloid leukemia. Genes, Chromosomes and Cancer, pp.918-950, 2006.

R. Standardized, analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-­?1 Concerted Action: investigation of minimal residual disease in acute leukemia, Leukemia, 1999.